{"gene":"HLA-DRA","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":2001,"finding":"CIITA coordinates multiple histone acetyltransferase activities at the HLA-DRA promoter in vivo: CIITA binding drives acetylation of both H3 and H4 histones, with a CIITA activation-domain mutant inducing H4 (at Lys8) but not H3 acetylation, indicating distinct HAT activities are recruited for each mark.","method":"In vivo chromatin analysis (time-course histone acetylation assays at HLA-DRA promoter), CIITA mutant expression","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — in vivo promoter occupancy and histone modification mapping with domain-specific mutants, single rigorous paper with multiple orthogonal readouts","pmids":["11429551"],"is_preprint":false},{"year":1991,"finding":"Two distinct X-box binding proteins regulate HLA-DRA transcription in B cells: RFX binds the X1 box (poorly to beta-chain gene promoters), while a separate factor X2BP binds the X2 box with high affinity and recognizes a different subset of class II promoters.","method":"Gel-mobility shift assays (EMSA), nuclear protein binding studies with HLA-DRA promoter fragments","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — direct DNA–protein binding with competition assays, foundational paper replicated across subsequent studies","pmids":["1956787"],"is_preprint":false},{"year":1992,"finding":"IFN-γ induces HLA-DRA expression in glioblastoma cells by upregulating X1 and X2 box protein–DNA interactions on a poised promoter while leaving other promoter contacts (octamer, Y box) unchanged; the octamer site is occupied in lymphoid but not in glioblastoma cells despite an open chromatin state.","method":"In vivo genomic footprinting in multiple cell lines ± IFN-γ treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — direct in vivo footprinting across multiple cell types with IFN-γ induction, strong mechanistic specificity","pmids":["1502171"],"is_preprint":false},{"year":1992,"finding":"Constitutive and IFN-γ-inducible transcription of HLA-DRA requires stereospecific alignment between the S and X elements (spacing changes abolish activity regardless of helical alignment) and between X and Y elements; these three elements function through a common pathway, likely via direct or indirect protein complex formation.","method":"Transient transfection of spacing/alignment mutant DRA promoter constructs in B cells and IFN-γ-treated fibroblasts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — systematic mutagenesis with defined functional readouts in multiple cell types","pmids":["1331098"],"is_preprint":false},{"year":1992,"finding":"Single base-pair substitutions in the HLA-DRA X1 and X2 boxes functionally separate their contributions: X1 and X2 mutations differentially affect B-cell transcription versus IFN-γ induction in fibroblasts, and in vivo X-box protein occupancy correlates with transcriptional activity.","method":"Site-directed mutagenesis of DRA promoter, transient transfection in B cells and IFN-γ-treated fibroblasts, EMSA","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — mutagenesis combined with in vivo occupancy data and functional reporter assays","pmids":["1560213"],"is_preprint":false},{"year":1990,"finding":"X-box binding proteins mediate both positive and negative transcriptional regulation of HLA-DRA via interaction with multiple upstream elements (W at −135 to −117, V at −193 to −179, and X box); gel-shift competition confirmed W- and V-bound proteins are the same as X-box-binding proteins.","method":"5′ promoter deletions, substitution mutants, nuclease S1 protection assays, EMSA with competition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple complementary methods mapping cis-elements and cognate trans-factors","pmids":["2120707"],"is_preprint":false},{"year":1992,"finding":"In primary astrocytes, IFN-γ regulation of HLA-DRA requires the S, X1 (but not X2), and Y promoter elements; IFN-γ induces a novel X-element-binding nuclear factor (IFNEX) in astrocytes that may underlie IFN-γ-mediated class II induction in this cell type.","method":"Site-specific mutagenesis of DRA promoter, transient transfection in primary astrocytes, EMSA with nuclear extracts","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — primary cells, mutagenesis and EMSA; IFNEX characterized only in single lab","pmids":["1588050"],"is_preprint":false},{"year":1992,"finding":"TNF-α synergizes with IFN-γ to activate HLA-DRA promoter activity through the W, X, and Y elements in astrocytes; combined cytokine treatment induces a novel, slower-mobility X-element DNA–protein complex (TIC-X) not seen with either cytokine alone.","method":"Transient transfection of DRA-CAT reporter in primary astrocytes, EMSA with nuclear extracts from cytokine-treated cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — primary cells, functional reporter assays plus EMSA; single lab","pmids":["1454841"],"is_preprint":false},{"year":1989,"finding":"The trans-acting factor RF-X binds to the HLA-DRA promoter and its absence (in hereditary class II immunodeficiency cells) abolishes two prominent DNase I-hypersensitive sites at the DRA promoter, linking RF-X binding to an open chromatin state necessary (but not sufficient) for DRA expression.","method":"DNase I hypersensitivity mapping in normal vs. class II-deficient B cells and IFN-γ-induced fibroblasts","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — chromatin structure analysis directly correlated with factor binding defect in patient-derived and normal cells","pmids":["2467188"],"is_preprint":false},{"year":1991,"finding":"RF-X binding to the HLA-DRA X1 box requires specific base pairs within the X box motif; single base-pair substitutions that eliminate RF-X binding also reduce expression, and natural/recombinant RF-X show identical binding-site specificity.","method":"EMSA with single-basepair substitution mutants of the DRA X box; comparison of natural and recombinant RF-X","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1/2 — systematic mutagenesis with functional validation using both natural and recombinant protein","pmids":["1903200"],"is_preprint":false},{"year":1991,"finding":"Mutant B-cell line 6.1.6 lacks a specific X-box DNA–protein complex (X-A, containing proteins of ~22, 32, 82, and 92 kDa) and shows greatly reduced DRA promoter activity in transfection assays; the same complex is absent in some class II-immunodeficient patient cell lines, implicating an X-box binding protein defect.","method":"Transient transfection of DRA promoter fragments, EMSA, UV cross-linking of X-A complex components","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — UV cross-linking identification of complex components plus functional transfection data; patient/mutant cell comparison","pmids":["1904083"],"is_preprint":false},{"year":2006,"finding":"TLR-triggered (CpG-DNA and LPS) HLA-DRA induction in human B cells requires NF-κB binding to the DRA promoter in addition to CIITA; IFN-γ-induced DRA expression depends on CIITA rather than NF-κB, revealing a distinct TLR-specific mechanism for MHC-II regulation.","method":"Dominant-negative CIITA and NF-κB constructs, RNAi, promoter mutant analysis, EMSA, chromatin immunoprecipitation (ChIP)","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple complementary methods (RNAi, dominant negative, EMSA, ChIP) in a single study","pmids":["16619292"],"is_preprint":false},{"year":2004,"finding":"Oct-1 represses the IFN-γ-inducible HLA-DRA gene in Rb-defective tumor cells by assembling a protein complex (DRAN) that blocks NF-Y access to the DRA promoter; Oct-1 antisense and TSA-induced promoter reactivation confirmed direct Oct-1 occupancy of the endogenous DRA promoter.","method":"Oct-1 antisense transformants, chromatin immunoprecipitation (ChIP), in vitro DNA–protein binding (EMSA), trichostatin A treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — antisense functional data confirmed by ChIP and in vitro binding assays; mechanistic model of NF-Y exclusion by Oct-1/DRAN complex","pmids":["15105429"],"is_preprint":false},{"year":2012,"finding":"Active HLA-DRA transcription is accompanied by nucleosome depletion at the proximal regulatory region and distribution of histone methylation (H3K4me3) and acetylation marks across the gene body; these modifications depend on RFX and CIITA binding, are stable through cell divisions after stimulus removal (epigenetic memory), and are laid down by MLL1 methyltransferase and GCN5 acetyltransferase complexes (ATAC/STAGA); some MLL complex components (MLL1, ASH2L, RbBP5) are CIITA-independent.","method":"Chromatin immunoprecipitation (ChIP) including dual cross-linking ChIP for histone-modifying complexes, in IFN-γ-induced epithelial cells, B cells, and B-cell MHC-II mutants","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — systematic ChIP across gene body in multiple cell types with mutant validation; dual cross-linking approach identifies specific complexes","pmids":["22701520"],"is_preprint":false},{"year":1995,"finding":"TRAX1, a novel X1-box-binding protein distinct from RFX1/NF-Xc/NF-X, was affinity-purified from HeLa nuclear extracts and shown by in vitro transcription assay to specifically activate HLA-DRA transcription; UV cross-linking estimated ~40 kDa; methylation interference showed TRAX1 contacts the 5′ end of the X1 box at −109/−108 with hypersensitive sites at −114/−113/−97.","method":"Affinity purification, in vitro transcription assay, EMSA, UV cross-linking, methylation interference","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro purification and functional transcription reconstitution with detailed footprinting","pmids":["7799935"],"is_preprint":false},{"year":1993,"finding":"hXBP-1 (a b-zip transcription factor) regulates HLA-DRA expression; the hXBP-1 promoter contains an X2-identical element (hX2) essential for hXBP-1 autoregulation; protein complexes that bind hX2 in the hXBP-1 promoter cross-compete with those binding the X2 element of the DRA promoter, and both promoters share a downstream Y-box element, demonstrating shared regulatory logic.","method":"Promoter deletion/mutagenesis, EMSA with cross-competition, chromosomal mapping of hXBP-1 pseudogene vs. functional gene","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis and EMSA; single lab","pmids":["8349596"],"is_preprint":false},{"year":1990,"finding":"In vitro transcription of the HLA-DRA promoter in B-cell vs. HeLa extracts shows complete dependence on the Y box (deletion reduces transcription by 95%) and partial dependence on the X box; the DRA octamer element does not activate transcription via OTF-2 in the same manner as immunoglobulin promoters in B cells.","method":"In vitro transcription assay with B-cell and HeLa cell nuclear extracts, 5′ deletion and internal deletion constructs","journal":"Tissue antigens","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro transcription reconstitution; single lab, no mutagenesis confirmation beyond deletions","pmids":["2278044"],"is_preprint":false},{"year":1994,"finding":"A sequence in the 3′ UTR of HLA-DRA mRNA functions as a nuclear retention signal; deletion of this region abrogates binding of compartmentalized nuclear/cytoplasmic proteins and releases DRA mRNA into the cytoplasm, indicating regulated nucleo-cytoplasmic partitioning of DRA transcripts by sequence-specific RNA–protein interactions.","method":"Transient transfection of DRA constructs with 3′ UTR deletions, RNA fractionation, RNA–protein binding assays in multiple cell lines","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — deletion mapping coupled with protein-binding and subcellular fractionation; single lab","pmids":["8028004"],"is_preprint":false},{"year":1992,"finding":"HLA-DRA expression in primary T lymphocytes upon mitogenic/antigenic activation is driven by a proximal 43-bp promoter element containing a TATTA motif; addition of upstream X and Y elements augments the response but can also suppress it in certain activation states; this is mechanistically distinct from transformed cell lines where X and Y are essential for basal expression.","method":"Transient transfection of DRA-CAT reporter constructs into primary human T lymphocytes, TATTA mutation, activation with mitogens/antigens","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — primary cell transfection with mutagenesis; single lab study","pmids":["1448091"],"is_preprint":false},{"year":1996,"finding":"The retinoblastoma (Rb) protein is required for IFN-γ induction of HLA-DRA (and HLA-DRB) mRNA in tumor cells; in Rb-defective non-small cell lung carcinoma H2009 cells, reconstitution of Rb rescues DRB but not DRA inducibility, demonstrating a specific defect at the DRA locus independent of general CIITA induction.","method":"Rb reconstitution in RB-defective tumor cells, IFN-γ treatment, Northern analysis of class II mRNA, CIITA mRNA analysis, surface DR flow cytometry","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — Rb reconstitution with multiple mRNA and protein readouts; single lab","pmids":["8786310"],"is_preprint":false},{"year":1993,"finding":"HLA-DRA transgenic mice expressing the DR alpha chain (as a mixed DR alpha/E beta heterodimer) demonstrate that the DR alpha/E beta pair supports negative selection (clonal deletion) of T cells bearing V beta 5, V beta 6, V beta 7, and V beta 11, with deletion efficiency correlating with the proportion of DR alpha-positive APCs; thymic epithelial cell expression of DR alpha E beta is sufficient for clonal deletion of superantigen-reactive T cells.","method":"Transgenic mouse models with X-linked HLA-DRA, T-cell repertoire analysis (V beta deletion), mixed lymphocyte reaction","journal":"Immunogenetics; European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo transgenic functional data with multiple V beta families and APC-specific expression lines; single organism model","pmids":["8420827","8100779"],"is_preprint":false},{"year":1998,"finding":"HLA-DRA1*0101/DRB1*0401 heterodimer expressed in Drosophila cells can present peptides to DRB1*0401-restricted T cells; Drosophila-expressed molecules have reduced N-linked glycosylation, higher peptide-binding capacity, and can be stabilized by high-affinity peptides, indicating the heterodimer's peptide-binding function does not require mammalian glycosylation.","method":"Recombinant expression in Drosophila Schneider 2 cells, flow cytometry, peptide-binding assays, SDS-PAGE, T-cell stimulation assay","journal":"Tissue antigens","confidence":"Medium","confidence_rationale":"Tier 1 — functional reconstitution with purified recombinant protein and T-cell assays; single study","pmids":["9510368"],"is_preprint":false},{"year":2020,"finding":"A splice acceptor variant (rs8084) in HLA-DRA mediates transcription of an alternative α-chain isoform lacking 25 amino acids in its extracellular domain; this short isoform cannot reach the cell surface (trapped in the ER and degraded) but retains the ability to bind the β-chain and can be transported to the membrane via interaction with the peptide-binding site of canonical HLA heterodimers.","method":"Molecular dynamics simulation, cellular trafficking experiments, co-expression with β-chain, endoplasmic reticulum localization assays, immunoprecipitation","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — combination of MD simulation and cellular trafficking experiments; single lab","pmids":["32986852"],"is_preprint":false},{"year":2022,"finding":"The short HLA-DRA isoform (sHLA-DRA, lacking 25 aa) binds to the outer domain of the HLA-DR2 peptide-binding site via a loop region (R69–G83) exposed only in the short isoform; F76 is critical for binding; sHLA-DRA allosterically modifies the peptide-binding pocket conformation of the canonical heterodimer.","method":"Atomistic molecular dynamics simulations, experimental mutagenesis of F76, binding assays","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 1/2 — MD simulation with experimental validation of key residue; single lab","pmids":["35218721"],"is_preprint":false},{"year":1995,"finding":"A far-upstream region of HLA-DRA contains X′ and Y′ boxes oriented in the opposite direction to the proximal X and Y boxes; DNase I footprinting and EMSA show these are specifically recognized by the same nuclear proteins that bind the proximal X and Y boxes, suggesting long-range regulatory interactions.","method":"DNase I footprinting, EMSA, sequence analysis and CpG analysis of far-upstream region","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — footprinting and EMSA; single lab","pmids":["7784170"],"is_preprint":false},{"year":1999,"finding":"Nuclear proteins bound to the far-upstream Y′ and X′ boxes of HLA-DRA can interact with proteins bound to the proximal Y and X boxes to form a stem-loop secondary structure; NF-Y was unambiguously identified as one of the proteins binding both Y and Y′ boxes by antibody supershift assay.","method":"Gel retardation (EMSA), DNase I footprinting, antibody supershift for NF-Y","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 — antibody supershift identifies NF-Y; stem-loop model supported by in vitro data; single lab","pmids":["10385003"],"is_preprint":false},{"year":2024,"finding":"Cuproptosis upregulates HLA-DRA expression at the transcriptional level (dose-dependently, via reactive oxygen species production), and high HLA-DRA levels promote chemokine expression (CCL5, CXCL9, CXCL10) and CD4+/CD8+ T-cell infiltration, synergizing with anti-PD-1 therapy in vivo to inhibit tumor growth.","method":"In vitro dose-response experiments, ROS measurement, in vivo mouse tumor model with anti-PD-1, immunohistochemistry, qRT-PCR for chemokines","journal":"Pharmaceuticals","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo mechanistic experiments; single lab, limited mechanistic depth on HLA-DRA-specific transcriptional pathway","pmids":["38931345"],"is_preprint":false},{"year":2026,"finding":"HLA-DRA regulates radiosensitivity of nasal mucosal epithelial cells: KO (CRISPR/Cas9) reduces apoptosis and suppresses IFN-γ and IL-6 expression after irradiation, while OE increases apoptosis and cytokine production; combined IL-6 and IFN-γ stimulation activates JAK-STAT signaling (STAT phosphorylation), placing HLA-DRA upstream of JAK-STAT pathway activation in radiation-induced sinusitis.","method":"CRISPR/Cas9 KO and OE of HLA-DRA in nasal epithelial cells, colony formation assay, CCK-8, flow cytometry for apoptosis, RT-qPCR, ELISA for cytokines, Western blot for STAT phosphorylation","journal":"Zhonghua er bi yan hou tou jing wai ke za zhi","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR KO and OE with multiple functional readouts; single lab study","pmids":["41956771"],"is_preprint":false}],"current_model":"HLA-DRA encodes the invariant α-chain of the HLA-DR class II heterodimer; its transcription is controlled by a multi-element proximal promoter (W, X1, X2, Y boxes and an octamer site) bound by factors including RFX (X1), NF-Y (Y box), CIITA (master coactivator recruiting histone acetyltransferases of the GCN5/ATAC/STAGA and MLL methyltransferase complexes), NF-κB (TLR pathway), and Oct-1 (repressor in Rb-defective cells via the DRAN complex blocking NF-Y), with stereospecific spacing constraints among elements required for both constitutive B-cell expression and IFN-γ-inducible expression; a splice variant (rs8084) generates a short isoform that is retained in the ER but can associate with canonical HLA-DR heterodimers via the outer peptide-binding domain, allosterically modifying their conformation."},"narrative":{"teleology":[{"year":1989,"claim":"Establishing that the trans-acting factor RF-X is required for an open chromatin state at HLA-DRA resolved how promoter accessibility is controlled: without RF-X (as in hereditary class II immunodeficiency), DNase I-hypersensitive sites at the DRA promoter are lost, showing that factor binding creates the permissive chromatin architecture necessary for transcription.","evidence":"DNase I hypersensitivity mapping in normal vs. class II-deficient B cells and IFN-γ-induced fibroblasts","pmids":["2467188"],"confidence":"High","gaps":["Identity of RF-X subunits not yet molecularly resolved at this stage","Whether RF-X binding is sufficient or only necessary for transcription unclear","Mechanism by which RF-X remodels chromatin not determined"]},{"year":1990,"claim":"Mapping the cis-regulatory architecture of HLA-DRA showed that X-box binding proteins mediate both positive and negative regulation through multiple upstream elements (W, V, X), and that the Y box is the dominant element for in vitro transcription, while the octamer does not function via OTF-2 as in immunoglobulin promoters.","evidence":"Promoter deletions, substitution mutants, nuclease S1 protection, EMSA, in vitro transcription in B-cell and HeLa extracts","pmids":["2120707","2278044"],"confidence":"High","gaps":["In vitro transcription system may not recapitulate chromatin-level regulation","Identity of Y-box binding factor not confirmed as NF-Y at this point"]},{"year":1991,"claim":"Dissection of the X box into functionally distinct X1 and X2 sub-elements, bound by RFX and a separate X2BP respectively, revealed that HLA-DRA transcription integrates at least two independent DNA-binding activities at the X region, each with different class II promoter specificities.","evidence":"EMSA with nuclear proteins, single-basepair mutagenesis of X box, comparison of natural and recombinant RF-X binding","pmids":["1956787","1903200","1904083"],"confidence":"High","gaps":["Molecular cloning of X2BP not achieved","Functional cooperativity between X1 and X2 factors not directly demonstrated"]},{"year":1992,"claim":"Stereospecific spacing between S, X, and Y elements was shown to be essential for both constitutive and IFN-γ-inducible DRA transcription, and IFN-γ acts by enhancing X1/X2 protein–DNA interactions on a poised promoter rather than by opening chromatin de novo, while cell-type-specific differences (astrocytes, glioblastoma, T cells) revealed distinct regulatory logics for the same promoter.","evidence":"Spacing/alignment mutant constructs in B cells and IFN-γ-treated fibroblasts; in vivo genomic footprinting across cell types; primary astrocyte transfection; primary T-cell reporter assays","pmids":["1331098","1502171","1560213","1588050","1448091","1454841"],"confidence":"High","gaps":["Nature of IFNEX and TIC-X novel complexes in astrocytes not molecularly defined","Mechanism of T-cell-specific TATTA-dependent activation not connected to known X/Y pathway"]},{"year":1994,"claim":"Discovery of a 3′ UTR nuclear retention signal in HLA-DRA mRNA established a post-transcriptional layer of regulation: sequence-specific RNA–protein interactions partition DRA transcripts between nucleus and cytoplasm, adding a previously unknown control point beyond transcription.","evidence":"3′ UTR deletion constructs, RNA fractionation, RNA–protein binding assays in multiple cell lines","pmids":["8028004"],"confidence":"Medium","gaps":["Identity of the RNA-binding proteins mediating retention not determined","Physiological conditions that regulate nuclear-cytoplasmic partitioning unknown","Not independently replicated"]},{"year":1995,"claim":"Identification of far-upstream X′ and Y′ boxes bound by the same factors as the proximal elements, and purification of TRAX1 as a novel X1-box activator, expanded the regulatory landscape of HLA-DRA and indicated long-range interactions potentially forming chromatin loop structures.","evidence":"Affinity purification and in vitro transcription reconstitution for TRAX1; DNase I footprinting and EMSA for far-upstream elements","pmids":["7799935","7784170"],"confidence":"High","gaps":["TRAX1 gene identity not cloned","Stem-loop model for far-upstream interaction only supported by in vitro data at this stage"]},{"year":1996,"claim":"Demonstrating that Rb is specifically required for IFN-γ induction of HLA-DRA in tumor cells—and that Rb reconstitution rescues DRB but not DRA—revealed a locus-specific silencing mechanism in Rb-defective cancers, separating DRA regulation from general CIITA availability.","evidence":"Rb reconstitution in Rb-defective tumor cells, Northern blot, CIITA mRNA analysis, surface DR flow cytometry","pmids":["8786310"],"confidence":"Medium","gaps":["Mechanism by which Rb acts specifically at DRA locus not identified","Single tumor cell line model"]},{"year":1999,"claim":"NF-Y was unambiguously confirmed as the factor binding both proximal Y and far-upstream Y′ boxes, and evidence for protein–protein interactions between proximal and distal element complexes supported a stem-loop chromatin architecture model for HLA-DRA regulation.","evidence":"Antibody supershift EMSA for NF-Y, DNase I footprinting of far-upstream region","pmids":["10385003"],"confidence":"Medium","gaps":["Stem-loop structure not validated in vivo (e.g., 3C/4C)","Functional significance of long-range interaction for transcription not tested by mutagenesis"]},{"year":2001,"claim":"CIITA was shown to coordinate distinct histone acetyltransferase activities at the HLA-DRA promoter in vivo—its activation domain mutant selectively loses H3 but retains H4 acetylation—establishing that CIITA acts as a scaffold recruiting multiple chromatin-modifying enzymes rather than a single HAT.","evidence":"In vivo chromatin analysis with time-course histone acetylation and CIITA activation-domain mutants","pmids":["11429551"],"confidence":"High","gaps":["Specific HAT enzymes responsible for H3 vs. H4 acetylation not identified in this study","Whether HAT recruitment is direct or via intermediary factors unknown"]},{"year":2004,"claim":"The Oct-1/DRAN complex was identified as a repressor that blocks NF-Y access to the HLA-DRA promoter in Rb-defective cells, mechanistically explaining the locus-specific silencing observed earlier and connecting Rb loss to epigenetic shutdown of DRA.","evidence":"Oct-1 antisense transformants, ChIP, EMSA, trichostatin A de-repression","pmids":["15105429"],"confidence":"High","gaps":["Composition of DRAN complex beyond Oct-1 not fully defined","Whether DRAN operates at other MHC-II loci not tested"]},{"year":2006,"claim":"Revealing that TLR-triggered HLA-DRA induction requires NF-κB binding to the DRA promoter—distinct from IFN-γ-mediated CIITA-dependent induction—established two parallel transcriptional pathways converging on the same gene, explaining how innate immune signals upregulate MHC-II independently of CIITA.","evidence":"Dominant-negative CIITA and NF-κB, RNAi, promoter mutants, EMSA, ChIP in human B cells","pmids":["16619292"],"confidence":"High","gaps":["NF-κB binding site in DRA promoter not precisely mapped relative to W/X/Y architecture","Whether NF-κB and CIITA pathways are mutually exclusive or additive not fully resolved"]},{"year":2012,"claim":"Systematic ChIP across the HLA-DRA gene body identified MLL1, GCN5, ATAC, and STAGA complexes as the histone-modifying machinery recruited by CIITA, with some MLL components (MLL1, ASH2L, RbBP5) being CIITA-independent; H3K4me3 and acetylation marks persist through cell divisions, constituting epigenetic memory of MHC-II activation.","evidence":"Dual cross-linking ChIP in IFN-γ-induced epithelial cells, B cells, and MHC-II mutant B cells","pmids":["22701520"],"confidence":"High","gaps":["Mechanism of CIITA-independent MLL1 recruitment not determined","Whether epigenetic memory requires continuous RFX occupancy not tested"]},{"year":2020,"claim":"Discovery that the rs8084 splice variant generates a short HLA-DRA isoform retained in the ER but capable of associating with canonical HLA-DR heterodimers revealed an unexpected protein-level regulatory mechanism by which alternative splicing can modify the functional conformation of surface MHC-II.","evidence":"Cellular trafficking experiments, co-expression with β-chain, ER localization assays, molecular dynamics simulations, mutagenesis of F76","pmids":["32986852","35218721"],"confidence":"Medium","gaps":["In vivo functional consequence of sHLA-DRA on antigen presentation not demonstrated","Population-level impact of rs8084 on immune responses unknown","Single-lab findings not independently replicated"]},{"year":2024,"claim":"Cuproptosis-driven ROS was shown to upregulate HLA-DRA transcription dose-dependently, and high HLA-DRA levels promoted chemokine expression and T-cell infiltration that synergized with anti-PD-1 therapy in vivo, linking HLA-DRA expression to tumor immune microenvironment remodeling.","evidence":"In vitro dose-response, ROS measurement, in vivo mouse tumor model with anti-PD-1, qRT-PCR for chemokines","pmids":["38931345"],"confidence":"Medium","gaps":["Transcriptional pathway from ROS to HLA-DRA not defined (CIITA vs. NF-κB involvement unknown)","Mouse model used murine system; direct human translational relevance not established"]},{"year":null,"claim":"Key unresolved questions include: the molecular identity and cloning of several DRA-specific trans-acting factors (TRAX1, X2BP, IFNEX, TIC-X); the in vivo validation of the proposed stem-loop chromatin architecture; the functional impact of the short HLA-DRA isoform on antigen presentation and T-cell responses; and the precise transcriptional pathway through which oxidative stress and cuproptosis activate HLA-DRA.","evidence":"","pmids":[],"confidence":"Low","gaps":["TRAX1/X2BP/IFNEX molecular identities remain unknown","Stem-loop model lacks chromosome conformation capture validation","sHLA-DRA functional impact on antigen presentation untested in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[21,22,23]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[21,22]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[22,23]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[20,21,26]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,11,13]}],"complexes":["HLA-DR (DRA/DRB heterodimer)"],"partners":["HLA-DRB1","CIITA","RFX1","NF-Y","OCT1","RELA"],"other_free_text":[]},"mechanistic_narrative":"HLA-DRA encodes the non-polymorphic α-chain of the MHC class II HLA-DR heterodimer, which presents peptide antigens to CD4+ T cells and participates in thymic negative selection of superantigen-reactive T cells [PMID:8420827, PMID:9510368]. Transcription of HLA-DRA is governed by a modular proximal promoter containing W, X1, X2, and Y boxes that must be stereospecifically aligned; RFX binds the X1 box to establish an open chromatin state, NF-Y occupies the Y box, and the master coactivator CIITA recruits distinct histone acetyltransferase (GCN5/ATAC/STAGA) and methyltransferase (MLL1) complexes to drive H3 and H4 modifications that constitute a stable epigenetic memory of activation [PMID:2467188, PMID:1331098, PMID:11429551, PMID:22701520]. IFN-γ-inducible expression proceeds through CIITA-dependent enhancement of X1/X2 occupancy, whereas TLR signaling activates HLA-DRA via NF-κB, and Oct-1 can repress the gene in Rb-defective tumor cells by assembling the DRAN complex that excludes NF-Y [PMID:1502171, PMID:16619292, PMID:15105429]. An alternative splice isoform lacking 25 extracellular amino acids (rs8084) is retained in the ER but associates with canonical HLA-DR heterodimers through its peptide-binding domain, allosterically modifying peptide-groove conformation [PMID:32986852, PMID:35218721]."},"prefetch_data":{"uniprot":{"accession":"P01903","full_name":"HLA class II histocompatibility antigen, DR alpha chain","aliases":["MHC class II antigen DRA"],"length_aa":254,"mass_kda":28.6,"function":"An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:15265931, PubMed:15322540, PubMed:17334368, PubMed:22327072, PubMed:24190431, PubMed:27591323, PubMed:29884618, PubMed:31495665, PubMed:8145819, PubMed:9075930). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819)","subcellular_location":"Cell membrane; Endoplasmic reticulum membrane; Early endosome membrane; Late endosome membrane; Lysosome membrane; Autolysosome membrane","url":"https://www.uniprot.org/uniprotkb/P01903/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HLA-DRA","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HLA-DRA","total_profiled":1310},"omim":[{"mim_id":"620818","title":"MHC CLASS II DEFICIENCY 5; MHC2D5","url":"https://www.omim.org/entry/620818"},{"mim_id":"620815","title":"MHC CLASS II DEFICIENCY 2; MHC2D2","url":"https://www.omim.org/entry/620815"},{"mim_id":"615746","title":"ZXD FAMILY ZINC FINGER PROTEIN C; ZXDC","url":"https://www.omim.org/entry/615746"},{"mim_id":"613725","title":"SOLUTE CARRIER FAMILY 25, MEMBER 17; SLC25A27","url":"https://www.omim.org/entry/613725"},{"mim_id":"613335","title":"MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 8; MARCHF8","url":"https://www.omim.org/entry/613335"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":931.1},{"tissue":"lymphoid tissue","ntpm":1196.6}],"url":"https://www.proteinatlas.org/search/HLA-DRA"},"hgnc":{"alias_symbol":[],"prev_symbol":["HLA-DRA1"]},"alphafold":{"accession":"P01903","domains":[{"cath_id":"3.10.320.10","chopping":"31-101","consensus_level":"high","plddt":94.4372,"start":31,"end":101},{"cath_id":"2.60.40.10","chopping":"112-203","consensus_level":"high","plddt":96.7587,"start":112,"end":203}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01903","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01903-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01903-F1-predicted_aligned_error_v6.png","plddt_mean":89.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HLA-DRA","jax_strain_url":"https://www.jax.org/strain/search?query=HLA-DRA"},"sequence":{"accession":"P01903","fasta_url":"https://rest.uniprot.org/uniprotkb/P01903.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01903/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01903"}},"corpus_meta":[{"pmid":"11429551","id":"PMC_11429551","title":"CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter.","date":"2001","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11429551","citation_count":151,"is_preprint":false},{"pmid":"1956787","id":"PMC_1956787","title":"Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1956787","citation_count":73,"is_preprint":false},{"pmid":"1502171","id":"PMC_1502171","title":"In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1502171","citation_count":68,"is_preprint":false},{"pmid":"25224099","id":"PMC_25224099","title":"HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping.","date":"2014","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25224099","citation_count":65,"is_preprint":false},{"pmid":"1560213","id":"PMC_1560213","title":"Single base pair substitutions within the HLA-DRA gene promoter separate the functions of the X1 and X2 boxes.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1560213","citation_count":64,"is_preprint":false},{"pmid":"20072847","id":"PMC_20072847","title":"Greater expression of TLR2, TLR4, and IL6 due to negative energy balance is associated with lower expression of HLA-DRA and HLA-A in bovine blood neutrophils after intramammary mastitis challenge with Streptococcus uberis.","date":"2010","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20072847","citation_count":59,"is_preprint":false},{"pmid":"1331098","id":"PMC_1331098","title":"Structural constraints within a trimeric transcriptional regulatory region. Constitutive and interferon-gamma-inducible expression of the HLA-DRA gene.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1331098","citation_count":50,"is_preprint":false},{"pmid":"24093602","id":"PMC_24093602","title":"Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis.","date":"2013","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24093602","citation_count":48,"is_preprint":false},{"pmid":"2120707","id":"PMC_2120707","title":"X-box-binding proteins positively and negatively regulate transcription of the HLA-DRA gene through interaction with discrete upstream W and V elements.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2120707","citation_count":46,"is_preprint":false},{"pmid":"1930684","id":"PMC_1930684","title":"Transcriptional regulation of the HLA-DRA gene.","date":"1991","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1930684","citation_count":39,"is_preprint":false},{"pmid":"2467188","id":"PMC_2467188","title":"Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene.","date":"1989","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2467188","citation_count":39,"is_preprint":false},{"pmid":"1588050","id":"PMC_1588050","title":"Usage of primary cells to delineate IFN-gamma-responsive DNA elements in the HLA-DRA promoter and to identify a novel IFN-gamma-enhanced nuclear factor.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1588050","citation_count":39,"is_preprint":false},{"pmid":"1401907","id":"PMC_1401907","title":"Localization of IFN-gamma receptor in first trimester placenta to trophoblasts but lack of stimulation of HLA-DRA, -DRB, or invariant chain mRNA expression by IFN-gamma.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1401907","citation_count":38,"is_preprint":false},{"pmid":"8786310","id":"PMC_8786310","title":"Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8786310","citation_count":38,"is_preprint":false},{"pmid":"1991973","id":"PMC_1991973","title":"The W element is a positive regulator of HLA-DRA transcription in various DR+ cell types.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1991973","citation_count":36,"is_preprint":false},{"pmid":"1904083","id":"PMC_1904083","title":"Defective HLA DRA X box binding in the class II transactive transcription factor mutant 6.1.6 and in cell lines from class II immunodeficient patients.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1904083","citation_count":36,"is_preprint":false},{"pmid":"16619292","id":"PMC_16619292","title":"Direct role of NF-kappaB activation in Toll-like receptor-triggered HLA-DRA expression.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16619292","citation_count":35,"is_preprint":false},{"pmid":"1454841","id":"PMC_1454841","title":"Tumor necrosis factor alpha response elements in the HLA-DRA promoter: identification of a tumor necrosis factor alpha-induced DNA-protein complex in astrocytes.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1454841","citation_count":32,"is_preprint":false},{"pmid":"1903200","id":"PMC_1903200","title":"Regulatory factor-X binding to mutant HLA-DRA promoter sequences.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1903200","citation_count":31,"is_preprint":false},{"pmid":"31617688","id":"PMC_31617688","title":"Insights into the polymorphism in HLA-DRA and its evolutionary relationship with HLA haplotypes.","date":"2019","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/31617688","citation_count":28,"is_preprint":false},{"pmid":"35794593","id":"PMC_35794593","title":"HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35794593","citation_count":27,"is_preprint":false},{"pmid":"8586413","id":"PMC_8586413","title":"A novel Creb family gene telomeric of HLA-DRA in the HLA complex.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8586413","citation_count":25,"is_preprint":false},{"pmid":"12648283","id":"PMC_12648283","title":"Relative quantification of HLA-DRA1 and -DQA1 expression by real-time reverse transcriptase-polymerase chain reaction (RT-PCR).","date":"2003","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12648283","citation_count":23,"is_preprint":false},{"pmid":"21067287","id":"PMC_21067287","title":"Multiple sclerosis risk markers in HLA-DRA, HLA-C, and IFNG genes are associated with sex-specific childhood leukemia risk.","date":"2010","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/21067287","citation_count":23,"is_preprint":false},{"pmid":"15105429","id":"PMC_15105429","title":"Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15105429","citation_count":22,"is_preprint":false},{"pmid":"35543859","id":"PMC_35543859","title":"Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35543859","citation_count":21,"is_preprint":false},{"pmid":"1448091","id":"PMC_1448091","title":"Activation of the HLA-DRA gene in primary human T lymphocytes: novel usage of TATA and the X and Y promoter elements.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1448091","citation_count":19,"is_preprint":false},{"pmid":"25319953","id":"PMC_25319953","title":"HLA-DRA is associated with Parkinson's disease in Iranian population.","date":"2014","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25319953","citation_count":19,"is_preprint":false},{"pmid":"1685491","id":"PMC_1685491","title":"Description of a polymorphism in the regulatory region of the HLA-DRA gene.","date":"1991","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1685491","citation_count":18,"is_preprint":false},{"pmid":"30962219","id":"PMC_30962219","title":"Genetic Variation Within the HLA-DRA1 Gene Modulates Susceptibility to Type 1 Diabetes in HLA-DR3 Homozygotes.","date":"2019","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30962219","citation_count":18,"is_preprint":false},{"pmid":"35208514","id":"PMC_35208514","title":"CD74 and HLA-DRA in Cervical Carcinogenesis: Potential Targets for Antitumour Therapy.","date":"2022","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/35208514","citation_count":17,"is_preprint":false},{"pmid":"2278044","id":"PMC_2278044","title":"Functional analysis of cis-linked regulatory sequences in the HLA DRA promoter by transcription in vitro.","date":"1990","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/2278044","citation_count":17,"is_preprint":false},{"pmid":"9510368","id":"PMC_9510368","title":"Functional characterization of HLA-DRA1*0101/DRB1*0401 molecules expressed in Drosophila melanogaster cells.","date":"1998","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/9510368","citation_count":16,"is_preprint":false},{"pmid":"22701520","id":"PMC_22701520","title":"Multiple histone methyl and acetyltransferase complex components bind the HLA-DRA gene.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22701520","citation_count":16,"is_preprint":false},{"pmid":"28881265","id":"PMC_28881265","title":"New variants near RHOJ and C2, HLA-DRA region and susceptibility to endometriosis in the Polish population-The genome-wide association study.","date":"2017","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/28881265","citation_count":16,"is_preprint":false},{"pmid":"8349596","id":"PMC_8349596","title":"The regulatory gene, hXBP-1, and its target, HLA-DRA, utilize both common and distinct regulatory elements and protein complexes.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8349596","citation_count":16,"is_preprint":false},{"pmid":"24039160","id":"PMC_24039160","title":"Reaffirmation of GAK, but not HLA-DRA, as a Parkinson's disease susceptibility gene in a Taiwanese population.","date":"2013","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24039160","citation_count":15,"is_preprint":false},{"pmid":"10527398","id":"PMC_10527398","title":"HLA-DMB gene and HLA-DRA promoter region polymorphisms in Australian multiple sclerosis patients.","date":"1999","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10527398","citation_count":15,"is_preprint":false},{"pmid":"22391069","id":"PMC_22391069","title":"HLA-DRA polymorphisms associated with risk of nasal polyposis in asthmatic patients.","date":"2012","source":"American journal of rhinology & allergy","url":"https://pubmed.ncbi.nlm.nih.gov/22391069","citation_count":15,"is_preprint":false},{"pmid":"28131168","id":"PMC_28131168","title":"HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort.","date":"2016","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28131168","citation_count":13,"is_preprint":false},{"pmid":"8420827","id":"PMC_8420827","title":"T-cell repertoire in a strain of transgenic C57BL/6 mice with the HLA-DRA gene on the X-chromosome.","date":"1993","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8420827","citation_count":13,"is_preprint":false},{"pmid":"8244778","id":"PMC_8244778","title":"Mouse mammary tumor virus-mediated T-cell receptor negative selection in HLA-DRA transgenic mice.","date":"1993","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8244778","citation_count":12,"is_preprint":false},{"pmid":"8028004","id":"PMC_8028004","title":"Control of nucleo-cytoplasmic HLA-DRA mRNA partitioning by interaction of a retention signal with compartmentalized proteins.","date":"1994","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8028004","citation_count":11,"is_preprint":false},{"pmid":"1721044","id":"PMC_1721044","title":"Tissue-specific expression of the HLA-DRA gene in transgenic mice.","date":"1991","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/1721044","citation_count":11,"is_preprint":false},{"pmid":"8100779","id":"PMC_8100779","title":"Restricted expression of transgenic HLA-DRA gene in thymic epithelial cells and its role in acquisition of T cell tolerance to self-superantigens and processed DR alpha-derived peptide.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8100779","citation_count":11,"is_preprint":false},{"pmid":"7799935","id":"PMC_7799935","title":"Affinity enrichment and functional characterization of TRAX1, a novel transcription activator and X1-sequence-binding protein of HLA-DRA.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7799935","citation_count":10,"is_preprint":false},{"pmid":"38931345","id":"PMC_38931345","title":"Improved Immunotherapy Outcomes via Cuproptosis Upregulation of HLA-DRA Expression: Promoting the Aggregation of CD4+ and CD8+T Lymphocytes in Clear Cell Renal Cell Carcinoma.","date":"2024","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38931345","citation_count":9,"is_preprint":false},{"pmid":"7784170","id":"PMC_7784170","title":"Sequencing of an upstream region of the human HLA-DRA gene containing X' and Y' boxes.","date":"1995","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/7784170","citation_count":9,"is_preprint":false},{"pmid":"1754710","id":"PMC_1754710","title":"Transcriptional regulation of HLA-DRA gene.","date":"1991","source":"Research in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1754710","citation_count":8,"is_preprint":false},{"pmid":"34311991","id":"PMC_34311991","title":"Tri-SNP polymorphism in the intron of HLA-DRA1 affects type 1 diabetes susceptibility in the Finnish population.","date":"2021","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34311991","citation_count":8,"is_preprint":false},{"pmid":"36132072","id":"PMC_36132072","title":"HLA-DRA Gene Polymorphisms Are Associated with Graves' Disease as an Autoimmune Thyroid Disease.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/36132072","citation_count":8,"is_preprint":false},{"pmid":"9187677","id":"PMC_9187677","title":"HLA-DRA promoter polymorphism and diversity generation within the immune system.","date":"1997","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9187677","citation_count":7,"is_preprint":false},{"pmid":"33178870","id":"PMC_33178870","title":"Analysis of Single Nucleotide Polymorphisms in HLA-DRA, IL2RA , and HMGB1 Genes in Multiple Sclerosis.","date":"2020","source":"Reports of biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33178870","citation_count":6,"is_preprint":false},{"pmid":"28862321","id":"PMC_28862321","title":"Expression of HLA-DRA and CD74 mRNA in whole blood during the course of complicated and uncomplicated Staphylococcus aureus bacteremia.","date":"2017","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28862321","citation_count":6,"is_preprint":false},{"pmid":"35895219","id":"PMC_35895219","title":"Genetic polymorphism of HLA-DRA and alcohol consumption affect hepatitis development in the Korean population.","date":"2022","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/35895219","citation_count":4,"is_preprint":false},{"pmid":"27073595","id":"PMC_27073595","title":"Association analysis of HLA-DRA in Chinese patients with sporadic Parkinson's disease.","date":"2015","source":"International journal of physiology, pathophysiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27073595","citation_count":4,"is_preprint":false},{"pmid":"32986852","id":"PMC_32986852","title":"A splice acceptor variant in HLA-DRA affects the conformation and cellular localization of the class II DR alpha-chain.","date":"2020","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32986852","citation_count":4,"is_preprint":false},{"pmid":"10385003","id":"PMC_10385003","title":"Analysis of the human HLA-DRA gene upstream region: evidence for a stem-loop array directed by nuclear factors.","date":"1999","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/10385003","citation_count":4,"is_preprint":false},{"pmid":"12445311","id":"PMC_12445311","title":"The HLA-DRA*0102 allele: correct nucleotide sequence and associated HLA haplotypes.","date":"2002","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/12445311","citation_count":4,"is_preprint":false},{"pmid":"9378957","id":"PMC_9378957","title":"In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9378957","citation_count":4,"is_preprint":false},{"pmid":"22890421","id":"PMC_22890421","title":"Common variants in HLA-DRA gene are associated with alcohol dependence in two Caucasian samples.","date":"2012","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/22890421","citation_count":3,"is_preprint":false},{"pmid":"35981747","id":"PMC_35981747","title":"Possible Relationship between the HLA-DRA1 Intron Haplotype of Three Single-Nucleotide Polymorphisms in Intron 1 of the HLA-DRA1 Gene and Autoantibodies in Children at Increased Genetic Risk for Autoimmune Type 1 Diabetes.","date":"2022","source":"ImmunoHorizons","url":"https://pubmed.ncbi.nlm.nih.gov/35981747","citation_count":3,"is_preprint":false},{"pmid":"38942763","id":"PMC_38942763","title":"Changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer's disease.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38942763","citation_count":3,"is_preprint":false},{"pmid":"16889686","id":"PMC_16889686","title":"Korean BAC library construction and characterization of HLA-DRA, HLA-DRB3.","date":"2006","source":"Journal of biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16889686","citation_count":3,"is_preprint":false},{"pmid":"34402606","id":"PMC_34402606","title":"Identification of three novel HLA-DRA alleles by next-generation sequencing.","date":"2021","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/34402606","citation_count":2,"is_preprint":false},{"pmid":"19280058","id":"PMC_19280058","title":"Technological advances in the study of HLA-DRA promoter regulation: extending the functions of CIITA, Oct-1, Rb, and RFX.","date":"2009","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/19280058","citation_count":2,"is_preprint":false},{"pmid":"15955077","id":"PMC_15955077","title":"Modular usage of the HLA-DRA promoter in extra-hematopoietic and hematopoietic cell types of transgenic mice.","date":"2005","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/15955077","citation_count":2,"is_preprint":false},{"pmid":"35218721","id":"PMC_35218721","title":"A short HLA-DRA isoform binds the HLA-DR2 heterodimer on the outer domain of the peptide-binding site.","date":"2022","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/35218721","citation_count":1,"is_preprint":false},{"pmid":"32253955","id":"PMC_32253955","title":"The rs3129882/rs4248166 in HLA-DRA and rs34372695 in SYT11 are not associated with sporadic Parkinson's disease in Central Chinese population.","date":"2020","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32253955","citation_count":1,"is_preprint":false},{"pmid":"40072812","id":"PMC_40072812","title":"Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients.","date":"2025","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40072812","citation_count":1,"is_preprint":false},{"pmid":"14612968","id":"PMC_14612968","title":"Identification of a novel DNase I hypersensitive site within the far upstream region of the human HLA-DRA gene.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14612968","citation_count":0,"is_preprint":false},{"pmid":"41956771","id":"PMC_41956771","title":"[Study on mechanism underlying the role of HLA-DRA in promoting radiation-induced sinusitis].","date":"2026","source":"Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/41956771","citation_count":0,"is_preprint":false},{"pmid":"22358954","id":"PMC_22358954","title":"Methylation state of the human HLA-DRa gene in transgenic mice.","date":"1991","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22358954","citation_count":0,"is_preprint":false},{"pmid":"40643781","id":"PMC_40643781","title":"Association of HLA-DRA, HLA-DQA1, and IL-6 gene variations with susceptibility to multiple sclerosis.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40643781","citation_count":0,"is_preprint":false},{"pmid":"41989255","id":"PMC_41989255","title":"Identification of the Novel HLA-DRA*01:20 Allele by Single Molecule, Real-Time DNA Sequencing.","date":"2026","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/41989255","citation_count":0,"is_preprint":false},{"pmid":"41232153","id":"PMC_41232153","title":"Role of HLA-DRA-CREB3L4 regulatory axis in the pathogenesis of ovarian endometriosis: Inhibition of CREB3L4 expression by HLA-DRA increases the risk of disease.","date":"2025","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41232153","citation_count":0,"is_preprint":false},{"pmid":"38168398","id":"PMC_38168398","title":"The Human Brainome: changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer's disease.","date":"2023","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/38168398","citation_count":0,"is_preprint":false},{"pmid":"41721874","id":"PMC_41721874","title":"Single-nucleus and machine-learning integration identifies HLA-DRA and FTL as immune-metabolic axes and traditional Chinese medicine-targetable hubs in calcific aortic valve disease.","date":"2026","source":"Journal of computer-aided molecular design","url":"https://pubmed.ncbi.nlm.nih.gov/41721874","citation_count":0,"is_preprint":false},{"pmid":"1534306","id":"PMC_1534306","title":"[Functional expression of xenogenic mixed isotype molecule, DR alpha E beta, in transgenic mice with HLA-DRA gene on X chromosome].","date":"1992","source":"Fukuoka igaku zasshi = Hukuoka acta medica","url":"https://pubmed.ncbi.nlm.nih.gov/1534306","citation_count":0,"is_preprint":false},{"pmid":"41627183","id":"PMC_41627183","title":"Polymorphisms in intron 1 of HLA-DRA differentially associate with type 1 diabetes and celiac disease and implicate involvement of complement system genes C4A and C4B.","date":"2026","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/41627183","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.29.25334740","title":"Unraveling the Single-Cell Spatial Landscapes of Melanoma Brain Metastases","date":"2025-09-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.29.25334740","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.11.675642","title":"Exhausted-like effector CD8 T cells mediate immune-stromal interactions at mucosal Chronic Graft-versus-Host Disease onset","date":"2025-09-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.11.675642","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.18.670793","title":"Spatial and Single-Cell Dissection of Fibroblast Subpopulation Reprogramming Driving Stromal Collapse in Breast Cancer Lymph Node Metastasis","date":"2025-08-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.18.670793","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.08.24311619","title":"Circulating pancreatic enzyme levels are a causal biomarker of type 1 diabetes","date":"2024-08-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.08.24311619","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.22.609211","title":"Remodelling of the glycome of B-cell precursor acute lymphoblastic leukemia cells developing drug-tolerance","date":"2024-08-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.22.609211","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.27.24311104","title":"Dual site proteomic analyses reveal potential drug targets for cardiovascular disease","date":"2024-07-29","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.27.24311104","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42342,"output_tokens":6710,"usd":0.113838},"stage2":{"model":"claude-opus-4-6","input_tokens":10532,"output_tokens":3814,"usd":0.222015},"total_usd":0.335853,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"CIITA coordinates multiple histone acetyltransferase activities at the HLA-DRA promoter in vivo: CIITA binding drives acetylation of both H3 and H4 histones, with a CIITA activation-domain mutant inducing H4 (at Lys8) but not H3 acetylation, indicating distinct HAT activities are recruited for each mark.\",\n      \"method\": \"In vivo chromatin analysis (time-course histone acetylation assays at HLA-DRA promoter), CIITA mutant expression\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo promoter occupancy and histone modification mapping with domain-specific mutants, single rigorous paper with multiple orthogonal readouts\",\n      \"pmids\": [\"11429551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Two distinct X-box binding proteins regulate HLA-DRA transcription in B cells: RFX binds the X1 box (poorly to beta-chain gene promoters), while a separate factor X2BP binds the X2 box with high affinity and recognizes a different subset of class II promoters.\",\n      \"method\": \"Gel-mobility shift assays (EMSA), nuclear protein binding studies with HLA-DRA promoter fragments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct DNA–protein binding with competition assays, foundational paper replicated across subsequent studies\",\n      \"pmids\": [\"1956787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"IFN-γ induces HLA-DRA expression in glioblastoma cells by upregulating X1 and X2 box protein–DNA interactions on a poised promoter while leaving other promoter contacts (octamer, Y box) unchanged; the octamer site is occupied in lymphoid but not in glioblastoma cells despite an open chromatin state.\",\n      \"method\": \"In vivo genomic footprinting in multiple cell lines ± IFN-γ treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo footprinting across multiple cell types with IFN-γ induction, strong mechanistic specificity\",\n      \"pmids\": [\"1502171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Constitutive and IFN-γ-inducible transcription of HLA-DRA requires stereospecific alignment between the S and X elements (spacing changes abolish activity regardless of helical alignment) and between X and Y elements; these three elements function through a common pathway, likely via direct or indirect protein complex formation.\",\n      \"method\": \"Transient transfection of spacing/alignment mutant DRA promoter constructs in B cells and IFN-γ-treated fibroblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis with defined functional readouts in multiple cell types\",\n      \"pmids\": [\"1331098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Single base-pair substitutions in the HLA-DRA X1 and X2 boxes functionally separate their contributions: X1 and X2 mutations differentially affect B-cell transcription versus IFN-γ induction in fibroblasts, and in vivo X-box protein occupancy correlates with transcriptional activity.\",\n      \"method\": \"Site-directed mutagenesis of DRA promoter, transient transfection in B cells and IFN-γ-treated fibroblasts, EMSA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis combined with in vivo occupancy data and functional reporter assays\",\n      \"pmids\": [\"1560213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"X-box binding proteins mediate both positive and negative transcriptional regulation of HLA-DRA via interaction with multiple upstream elements (W at −135 to −117, V at −193 to −179, and X box); gel-shift competition confirmed W- and V-bound proteins are the same as X-box-binding proteins.\",\n      \"method\": \"5′ promoter deletions, substitution mutants, nuclease S1 protection assays, EMSA with competition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple complementary methods mapping cis-elements and cognate trans-factors\",\n      \"pmids\": [\"2120707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"In primary astrocytes, IFN-γ regulation of HLA-DRA requires the S, X1 (but not X2), and Y promoter elements; IFN-γ induces a novel X-element-binding nuclear factor (IFNEX) in astrocytes that may underlie IFN-γ-mediated class II induction in this cell type.\",\n      \"method\": \"Site-specific mutagenesis of DRA promoter, transient transfection in primary astrocytes, EMSA with nuclear extracts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — primary cells, mutagenesis and EMSA; IFNEX characterized only in single lab\",\n      \"pmids\": [\"1588050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"TNF-α synergizes with IFN-γ to activate HLA-DRA promoter activity through the W, X, and Y elements in astrocytes; combined cytokine treatment induces a novel, slower-mobility X-element DNA–protein complex (TIC-X) not seen with either cytokine alone.\",\n      \"method\": \"Transient transfection of DRA-CAT reporter in primary astrocytes, EMSA with nuclear extracts from cytokine-treated cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — primary cells, functional reporter assays plus EMSA; single lab\",\n      \"pmids\": [\"1454841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The trans-acting factor RF-X binds to the HLA-DRA promoter and its absence (in hereditary class II immunodeficiency cells) abolishes two prominent DNase I-hypersensitive sites at the DRA promoter, linking RF-X binding to an open chromatin state necessary (but not sufficient) for DRA expression.\",\n      \"method\": \"DNase I hypersensitivity mapping in normal vs. class II-deficient B cells and IFN-γ-induced fibroblasts\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chromatin structure analysis directly correlated with factor binding defect in patient-derived and normal cells\",\n      \"pmids\": [\"2467188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"RF-X binding to the HLA-DRA X1 box requires specific base pairs within the X box motif; single base-pair substitutions that eliminate RF-X binding also reduce expression, and natural/recombinant RF-X show identical binding-site specificity.\",\n      \"method\": \"EMSA with single-basepair substitution mutants of the DRA X box; comparison of natural and recombinant RF-X\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — systematic mutagenesis with functional validation using both natural and recombinant protein\",\n      \"pmids\": [\"1903200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Mutant B-cell line 6.1.6 lacks a specific X-box DNA–protein complex (X-A, containing proteins of ~22, 32, 82, and 92 kDa) and shows greatly reduced DRA promoter activity in transfection assays; the same complex is absent in some class II-immunodeficient patient cell lines, implicating an X-box binding protein defect.\",\n      \"method\": \"Transient transfection of DRA promoter fragments, EMSA, UV cross-linking of X-A complex components\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — UV cross-linking identification of complex components plus functional transfection data; patient/mutant cell comparison\",\n      \"pmids\": [\"1904083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TLR-triggered (CpG-DNA and LPS) HLA-DRA induction in human B cells requires NF-κB binding to the DRA promoter in addition to CIITA; IFN-γ-induced DRA expression depends on CIITA rather than NF-κB, revealing a distinct TLR-specific mechanism for MHC-II regulation.\",\n      \"method\": \"Dominant-negative CIITA and NF-κB constructs, RNAi, promoter mutant analysis, EMSA, chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple complementary methods (RNAi, dominant negative, EMSA, ChIP) in a single study\",\n      \"pmids\": [\"16619292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Oct-1 represses the IFN-γ-inducible HLA-DRA gene in Rb-defective tumor cells by assembling a protein complex (DRAN) that blocks NF-Y access to the DRA promoter; Oct-1 antisense and TSA-induced promoter reactivation confirmed direct Oct-1 occupancy of the endogenous DRA promoter.\",\n      \"method\": \"Oct-1 antisense transformants, chromatin immunoprecipitation (ChIP), in vitro DNA–protein binding (EMSA), trichostatin A treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — antisense functional data confirmed by ChIP and in vitro binding assays; mechanistic model of NF-Y exclusion by Oct-1/DRAN complex\",\n      \"pmids\": [\"15105429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Active HLA-DRA transcription is accompanied by nucleosome depletion at the proximal regulatory region and distribution of histone methylation (H3K4me3) and acetylation marks across the gene body; these modifications depend on RFX and CIITA binding, are stable through cell divisions after stimulus removal (epigenetic memory), and are laid down by MLL1 methyltransferase and GCN5 acetyltransferase complexes (ATAC/STAGA); some MLL complex components (MLL1, ASH2L, RbBP5) are CIITA-independent.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) including dual cross-linking ChIP for histone-modifying complexes, in IFN-γ-induced epithelial cells, B cells, and B-cell MHC-II mutants\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic ChIP across gene body in multiple cell types with mutant validation; dual cross-linking approach identifies specific complexes\",\n      \"pmids\": [\"22701520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TRAX1, a novel X1-box-binding protein distinct from RFX1/NF-Xc/NF-X, was affinity-purified from HeLa nuclear extracts and shown by in vitro transcription assay to specifically activate HLA-DRA transcription; UV cross-linking estimated ~40 kDa; methylation interference showed TRAX1 contacts the 5′ end of the X1 box at −109/−108 with hypersensitive sites at −114/−113/−97.\",\n      \"method\": \"Affinity purification, in vitro transcription assay, EMSA, UV cross-linking, methylation interference\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro purification and functional transcription reconstitution with detailed footprinting\",\n      \"pmids\": [\"7799935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"hXBP-1 (a b-zip transcription factor) regulates HLA-DRA expression; the hXBP-1 promoter contains an X2-identical element (hX2) essential for hXBP-1 autoregulation; protein complexes that bind hX2 in the hXBP-1 promoter cross-compete with those binding the X2 element of the DRA promoter, and both promoters share a downstream Y-box element, demonstrating shared regulatory logic.\",\n      \"method\": \"Promoter deletion/mutagenesis, EMSA with cross-competition, chromosomal mapping of hXBP-1 pseudogene vs. functional gene\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis and EMSA; single lab\",\n      \"pmids\": [\"8349596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"In vitro transcription of the HLA-DRA promoter in B-cell vs. HeLa extracts shows complete dependence on the Y box (deletion reduces transcription by 95%) and partial dependence on the X box; the DRA octamer element does not activate transcription via OTF-2 in the same manner as immunoglobulin promoters in B cells.\",\n      \"method\": \"In vitro transcription assay with B-cell and HeLa cell nuclear extracts, 5′ deletion and internal deletion constructs\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro transcription reconstitution; single lab, no mutagenesis confirmation beyond deletions\",\n      \"pmids\": [\"2278044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A sequence in the 3′ UTR of HLA-DRA mRNA functions as a nuclear retention signal; deletion of this region abrogates binding of compartmentalized nuclear/cytoplasmic proteins and releases DRA mRNA into the cytoplasm, indicating regulated nucleo-cytoplasmic partitioning of DRA transcripts by sequence-specific RNA–protein interactions.\",\n      \"method\": \"Transient transfection of DRA constructs with 3′ UTR deletions, RNA fractionation, RNA–protein binding assays in multiple cell lines\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — deletion mapping coupled with protein-binding and subcellular fractionation; single lab\",\n      \"pmids\": [\"8028004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"HLA-DRA expression in primary T lymphocytes upon mitogenic/antigenic activation is driven by a proximal 43-bp promoter element containing a TATTA motif; addition of upstream X and Y elements augments the response but can also suppress it in certain activation states; this is mechanistically distinct from transformed cell lines where X and Y are essential for basal expression.\",\n      \"method\": \"Transient transfection of DRA-CAT reporter constructs into primary human T lymphocytes, TATTA mutation, activation with mitogens/antigens\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — primary cell transfection with mutagenesis; single lab study\",\n      \"pmids\": [\"1448091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The retinoblastoma (Rb) protein is required for IFN-γ induction of HLA-DRA (and HLA-DRB) mRNA in tumor cells; in Rb-defective non-small cell lung carcinoma H2009 cells, reconstitution of Rb rescues DRB but not DRA inducibility, demonstrating a specific defect at the DRA locus independent of general CIITA induction.\",\n      \"method\": \"Rb reconstitution in RB-defective tumor cells, IFN-γ treatment, Northern analysis of class II mRNA, CIITA mRNA analysis, surface DR flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Rb reconstitution with multiple mRNA and protein readouts; single lab\",\n      \"pmids\": [\"8786310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"HLA-DRA transgenic mice expressing the DR alpha chain (as a mixed DR alpha/E beta heterodimer) demonstrate that the DR alpha/E beta pair supports negative selection (clonal deletion) of T cells bearing V beta 5, V beta 6, V beta 7, and V beta 11, with deletion efficiency correlating with the proportion of DR alpha-positive APCs; thymic epithelial cell expression of DR alpha E beta is sufficient for clonal deletion of superantigen-reactive T cells.\",\n      \"method\": \"Transgenic mouse models with X-linked HLA-DRA, T-cell repertoire analysis (V beta deletion), mixed lymphocyte reaction\",\n      \"journal\": \"Immunogenetics; European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic functional data with multiple V beta families and APC-specific expression lines; single organism model\",\n      \"pmids\": [\"8420827\", \"8100779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HLA-DRA1*0101/DRB1*0401 heterodimer expressed in Drosophila cells can present peptides to DRB1*0401-restricted T cells; Drosophila-expressed molecules have reduced N-linked glycosylation, higher peptide-binding capacity, and can be stabilized by high-affinity peptides, indicating the heterodimer's peptide-binding function does not require mammalian glycosylation.\",\n      \"method\": \"Recombinant expression in Drosophila Schneider 2 cells, flow cytometry, peptide-binding assays, SDS-PAGE, T-cell stimulation assay\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution with purified recombinant protein and T-cell assays; single study\",\n      \"pmids\": [\"9510368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A splice acceptor variant (rs8084) in HLA-DRA mediates transcription of an alternative α-chain isoform lacking 25 amino acids in its extracellular domain; this short isoform cannot reach the cell surface (trapped in the ER and degraded) but retains the ability to bind the β-chain and can be transported to the membrane via interaction with the peptide-binding site of canonical HLA heterodimers.\",\n      \"method\": \"Molecular dynamics simulation, cellular trafficking experiments, co-expression with β-chain, endoplasmic reticulum localization assays, immunoprecipitation\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — combination of MD simulation and cellular trafficking experiments; single lab\",\n      \"pmids\": [\"32986852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The short HLA-DRA isoform (sHLA-DRA, lacking 25 aa) binds to the outer domain of the HLA-DR2 peptide-binding site via a loop region (R69–G83) exposed only in the short isoform; F76 is critical for binding; sHLA-DRA allosterically modifies the peptide-binding pocket conformation of the canonical heterodimer.\",\n      \"method\": \"Atomistic molecular dynamics simulations, experimental mutagenesis of F76, binding assays\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — MD simulation with experimental validation of key residue; single lab\",\n      \"pmids\": [\"35218721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A far-upstream region of HLA-DRA contains X′ and Y′ boxes oriented in the opposite direction to the proximal X and Y boxes; DNase I footprinting and EMSA show these are specifically recognized by the same nuclear proteins that bind the proximal X and Y boxes, suggesting long-range regulatory interactions.\",\n      \"method\": \"DNase I footprinting, EMSA, sequence analysis and CpG analysis of far-upstream region\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — footprinting and EMSA; single lab\",\n      \"pmids\": [\"7784170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Nuclear proteins bound to the far-upstream Y′ and X′ boxes of HLA-DRA can interact with proteins bound to the proximal Y and X boxes to form a stem-loop secondary structure; NF-Y was unambiguously identified as one of the proteins binding both Y and Y′ boxes by antibody supershift assay.\",\n      \"method\": \"Gel retardation (EMSA), DNase I footprinting, antibody supershift for NF-Y\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody supershift identifies NF-Y; stem-loop model supported by in vitro data; single lab\",\n      \"pmids\": [\"10385003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cuproptosis upregulates HLA-DRA expression at the transcriptional level (dose-dependently, via reactive oxygen species production), and high HLA-DRA levels promote chemokine expression (CCL5, CXCL9, CXCL10) and CD4+/CD8+ T-cell infiltration, synergizing with anti-PD-1 therapy in vivo to inhibit tumor growth.\",\n      \"method\": \"In vitro dose-response experiments, ROS measurement, in vivo mouse tumor model with anti-PD-1, immunohistochemistry, qRT-PCR for chemokines\",\n      \"journal\": \"Pharmaceuticals\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo mechanistic experiments; single lab, limited mechanistic depth on HLA-DRA-specific transcriptional pathway\",\n      \"pmids\": [\"38931345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"HLA-DRA regulates radiosensitivity of nasal mucosal epithelial cells: KO (CRISPR/Cas9) reduces apoptosis and suppresses IFN-γ and IL-6 expression after irradiation, while OE increases apoptosis and cytokine production; combined IL-6 and IFN-γ stimulation activates JAK-STAT signaling (STAT phosphorylation), placing HLA-DRA upstream of JAK-STAT pathway activation in radiation-induced sinusitis.\",\n      \"method\": \"CRISPR/Cas9 KO and OE of HLA-DRA in nasal epithelial cells, colony formation assay, CCK-8, flow cytometry for apoptosis, RT-qPCR, ELISA for cytokines, Western blot for STAT phosphorylation\",\n      \"journal\": \"Zhonghua er bi yan hou tou jing wai ke za zhi\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO and OE with multiple functional readouts; single lab study\",\n      \"pmids\": [\"41956771\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLA-DRA encodes the invariant α-chain of the HLA-DR class II heterodimer; its transcription is controlled by a multi-element proximal promoter (W, X1, X2, Y boxes and an octamer site) bound by factors including RFX (X1), NF-Y (Y box), CIITA (master coactivator recruiting histone acetyltransferases of the GCN5/ATAC/STAGA and MLL methyltransferase complexes), NF-κB (TLR pathway), and Oct-1 (repressor in Rb-defective cells via the DRAN complex blocking NF-Y), with stereospecific spacing constraints among elements required for both constitutive B-cell expression and IFN-γ-inducible expression; a splice variant (rs8084) generates a short isoform that is retained in the ER but can associate with canonical HLA-DR heterodimers via the outer peptide-binding domain, allosterically modifying their conformation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"HLA-DRA encodes the non-polymorphic α-chain of the MHC class II HLA-DR heterodimer, which presents peptide antigens to CD4+ T cells and participates in thymic negative selection of superantigen-reactive T cells [PMID:8420827, PMID:9510368]. Transcription of HLA-DRA is governed by a modular proximal promoter containing W, X1, X2, and Y boxes that must be stereospecifically aligned; RFX binds the X1 box to establish an open chromatin state, NF-Y occupies the Y box, and the master coactivator CIITA recruits distinct histone acetyltransferase (GCN5/ATAC/STAGA) and methyltransferase (MLL1) complexes to drive H3 and H4 modifications that constitute a stable epigenetic memory of activation [PMID:2467188, PMID:1331098, PMID:11429551, PMID:22701520]. IFN-γ-inducible expression proceeds through CIITA-dependent enhancement of X1/X2 occupancy, whereas TLR signaling activates HLA-DRA via NF-κB, and Oct-1 can repress the gene in Rb-defective tumor cells by assembling the DRAN complex that excludes NF-Y [PMID:1502171, PMID:16619292, PMID:15105429]. An alternative splice isoform lacking 25 extracellular amino acids (rs8084) is retained in the ER but associates with canonical HLA-DR heterodimers through its peptide-binding domain, allosterically modifying peptide-groove conformation [PMID:32986852, PMID:35218721].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Establishing that the trans-acting factor RF-X is required for an open chromatin state at HLA-DRA resolved how promoter accessibility is controlled: without RF-X (as in hereditary class II immunodeficiency), DNase I-hypersensitive sites at the DRA promoter are lost, showing that factor binding creates the permissive chromatin architecture necessary for transcription.\",\n      \"evidence\": \"DNase I hypersensitivity mapping in normal vs. class II-deficient B cells and IFN-γ-induced fibroblasts\",\n      \"pmids\": [\"2467188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of RF-X subunits not yet molecularly resolved at this stage\", \"Whether RF-X binding is sufficient or only necessary for transcription unclear\", \"Mechanism by which RF-X remodels chromatin not determined\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Mapping the cis-regulatory architecture of HLA-DRA showed that X-box binding proteins mediate both positive and negative regulation through multiple upstream elements (W, V, X), and that the Y box is the dominant element for in vitro transcription, while the octamer does not function via OTF-2 as in immunoglobulin promoters.\",\n      \"evidence\": \"Promoter deletions, substitution mutants, nuclease S1 protection, EMSA, in vitro transcription in B-cell and HeLa extracts\",\n      \"pmids\": [\"2120707\", \"2278044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro transcription system may not recapitulate chromatin-level regulation\", \"Identity of Y-box binding factor not confirmed as NF-Y at this point\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Dissection of the X box into functionally distinct X1 and X2 sub-elements, bound by RFX and a separate X2BP respectively, revealed that HLA-DRA transcription integrates at least two independent DNA-binding activities at the X region, each with different class II promoter specificities.\",\n      \"evidence\": \"EMSA with nuclear proteins, single-basepair mutagenesis of X box, comparison of natural and recombinant RF-X binding\",\n      \"pmids\": [\"1956787\", \"1903200\", \"1904083\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular cloning of X2BP not achieved\", \"Functional cooperativity between X1 and X2 factors not directly demonstrated\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Stereospecific spacing between S, X, and Y elements was shown to be essential for both constitutive and IFN-γ-inducible DRA transcription, and IFN-γ acts by enhancing X1/X2 protein–DNA interactions on a poised promoter rather than by opening chromatin de novo, while cell-type-specific differences (astrocytes, glioblastoma, T cells) revealed distinct regulatory logics for the same promoter.\",\n      \"evidence\": \"Spacing/alignment mutant constructs in B cells and IFN-γ-treated fibroblasts; in vivo genomic footprinting across cell types; primary astrocyte transfection; primary T-cell reporter assays\",\n      \"pmids\": [\"1331098\", \"1502171\", \"1560213\", \"1588050\", \"1448091\", \"1454841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of IFNEX and TIC-X novel complexes in astrocytes not molecularly defined\", \"Mechanism of T-cell-specific TATTA-dependent activation not connected to known X/Y pathway\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Discovery of a 3′ UTR nuclear retention signal in HLA-DRA mRNA established a post-transcriptional layer of regulation: sequence-specific RNA–protein interactions partition DRA transcripts between nucleus and cytoplasm, adding a previously unknown control point beyond transcription.\",\n      \"evidence\": \"3′ UTR deletion constructs, RNA fractionation, RNA–protein binding assays in multiple cell lines\",\n      \"pmids\": [\"8028004\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the RNA-binding proteins mediating retention not determined\", \"Physiological conditions that regulate nuclear-cytoplasmic partitioning unknown\", \"Not independently replicated\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of far-upstream X′ and Y′ boxes bound by the same factors as the proximal elements, and purification of TRAX1 as a novel X1-box activator, expanded the regulatory landscape of HLA-DRA and indicated long-range interactions potentially forming chromatin loop structures.\",\n      \"evidence\": \"Affinity purification and in vitro transcription reconstitution for TRAX1; DNase I footprinting and EMSA for far-upstream elements\",\n      \"pmids\": [\"7799935\", \"7784170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TRAX1 gene identity not cloned\", \"Stem-loop model for far-upstream interaction only supported by in vitro data at this stage\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that Rb is specifically required for IFN-γ induction of HLA-DRA in tumor cells—and that Rb reconstitution rescues DRB but not DRA—revealed a locus-specific silencing mechanism in Rb-defective cancers, separating DRA regulation from general CIITA availability.\",\n      \"evidence\": \"Rb reconstitution in Rb-defective tumor cells, Northern blot, CIITA mRNA analysis, surface DR flow cytometry\",\n      \"pmids\": [\"8786310\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which Rb acts specifically at DRA locus not identified\", \"Single tumor cell line model\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"NF-Y was unambiguously confirmed as the factor binding both proximal Y and far-upstream Y′ boxes, and evidence for protein–protein interactions between proximal and distal element complexes supported a stem-loop chromatin architecture model for HLA-DRA regulation.\",\n      \"evidence\": \"Antibody supershift EMSA for NF-Y, DNase I footprinting of far-upstream region\",\n      \"pmids\": [\"10385003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stem-loop structure not validated in vivo (e.g., 3C/4C)\", \"Functional significance of long-range interaction for transcription not tested by mutagenesis\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"CIITA was shown to coordinate distinct histone acetyltransferase activities at the HLA-DRA promoter in vivo—its activation domain mutant selectively loses H3 but retains H4 acetylation—establishing that CIITA acts as a scaffold recruiting multiple chromatin-modifying enzymes rather than a single HAT.\",\n      \"evidence\": \"In vivo chromatin analysis with time-course histone acetylation and CIITA activation-domain mutants\",\n      \"pmids\": [\"11429551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HAT enzymes responsible for H3 vs. H4 acetylation not identified in this study\", \"Whether HAT recruitment is direct or via intermediary factors unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The Oct-1/DRAN complex was identified as a repressor that blocks NF-Y access to the HLA-DRA promoter in Rb-defective cells, mechanistically explaining the locus-specific silencing observed earlier and connecting Rb loss to epigenetic shutdown of DRA.\",\n      \"evidence\": \"Oct-1 antisense transformants, ChIP, EMSA, trichostatin A de-repression\",\n      \"pmids\": [\"15105429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Composition of DRAN complex beyond Oct-1 not fully defined\", \"Whether DRAN operates at other MHC-II loci not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealing that TLR-triggered HLA-DRA induction requires NF-κB binding to the DRA promoter—distinct from IFN-γ-mediated CIITA-dependent induction—established two parallel transcriptional pathways converging on the same gene, explaining how innate immune signals upregulate MHC-II independently of CIITA.\",\n      \"evidence\": \"Dominant-negative CIITA and NF-κB, RNAi, promoter mutants, EMSA, ChIP in human B cells\",\n      \"pmids\": [\"16619292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NF-κB binding site in DRA promoter not precisely mapped relative to W/X/Y architecture\", \"Whether NF-κB and CIITA pathways are mutually exclusive or additive not fully resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Systematic ChIP across the HLA-DRA gene body identified MLL1, GCN5, ATAC, and STAGA complexes as the histone-modifying machinery recruited by CIITA, with some MLL components (MLL1, ASH2L, RbBP5) being CIITA-independent; H3K4me3 and acetylation marks persist through cell divisions, constituting epigenetic memory of MHC-II activation.\",\n      \"evidence\": \"Dual cross-linking ChIP in IFN-γ-induced epithelial cells, B cells, and MHC-II mutant B cells\",\n      \"pmids\": [\"22701520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of CIITA-independent MLL1 recruitment not determined\", \"Whether epigenetic memory requires continuous RFX occupancy not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery that the rs8084 splice variant generates a short HLA-DRA isoform retained in the ER but capable of associating with canonical HLA-DR heterodimers revealed an unexpected protein-level regulatory mechanism by which alternative splicing can modify the functional conformation of surface MHC-II.\",\n      \"evidence\": \"Cellular trafficking experiments, co-expression with β-chain, ER localization assays, molecular dynamics simulations, mutagenesis of F76\",\n      \"pmids\": [\"32986852\", \"35218721\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo functional consequence of sHLA-DRA on antigen presentation not demonstrated\", \"Population-level impact of rs8084 on immune responses unknown\", \"Single-lab findings not independently replicated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cuproptosis-driven ROS was shown to upregulate HLA-DRA transcription dose-dependently, and high HLA-DRA levels promoted chemokine expression and T-cell infiltration that synergized with anti-PD-1 therapy in vivo, linking HLA-DRA expression to tumor immune microenvironment remodeling.\",\n      \"evidence\": \"In vitro dose-response, ROS measurement, in vivo mouse tumor model with anti-PD-1, qRT-PCR for chemokines\",\n      \"pmids\": [\"38931345\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional pathway from ROS to HLA-DRA not defined (CIITA vs. NF-κB involvement unknown)\", \"Mouse model used murine system; direct human translational relevance not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the molecular identity and cloning of several DRA-specific trans-acting factors (TRAX1, X2BP, IFNEX, TIC-X); the in vivo validation of the proposed stem-loop chromatin architecture; the functional impact of the short HLA-DRA isoform on antigen presentation and T-cell responses; and the precise transcriptional pathway through which oxidative stress and cuproptosis activate HLA-DRA.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"TRAX1/X2BP/IFNEX molecular identities remain unknown\", \"Stem-loop model lacks chromosome conformation capture validation\", \"sHLA-DRA functional impact on antigen presentation untested in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [21, 22, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [21, 22]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [22, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [20, 21, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 11, 13]}\n    ],\n    \"complexes\": [\n      \"HLA-DR (DRA/DRB heterodimer)\"\n    ],\n    \"partners\": [\n      \"HLA-DRB1\",\n      \"CIITA\",\n      \"RFX1\",\n      \"NF-Y\",\n      \"OCT1\",\n      \"RELA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}